Skip to main content
Download PDF

Volume 2 Supplement 1

2005 International Meeting of The Institute of Human Virology

  • Poster presentation
  • Open access
  • Published:

Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen

Retrovirology volume 2, Article number: P61 (2005) Cite this article

In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.

Author information

Authors and Affiliations

  1. L'Association Soliderite Sainte, Congo, Africa

    Viviane Loungoussou

Authors
  1. Viviane Loungoussou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Viviane Loungoussou.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Loungoussou, V. Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen. Retrovirology 2 (Suppl 1), P61 (2005). https://doi.org/10.1186/1742-4690-2-S1-P61

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1742-4690-2-S1-P61

Keywords